← Leaderboards
Fadia Ali Kamal
Pennsylvania State Univ Hershey Med Ctr
$1,672,809
Attributed
$1,672,809
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $337.3K · FY2019–23$500K$375K$250K$125K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,672,809 · 1
By mechanism
R01$1,672,809 · 1
Top collaborators
No co-investigators on record.
Most similar at Pennsylvania State Univ Hershey Med Ctr
Same institution · by research overlap
- Sivaraj Sivaramakrishnan$9,486,784
- John Spence Reid$621,542
- Jun You$1,640,917
- Gregory Stephen Lewis$710,872
- Matthew D Coates$1,528,645
Others in their field
Other Emerging Leaders on “Future”
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- John E West · University Of Texas At Austin$128,483,161
- Beth Baseler · Leidos Biomedical Research, Inc.$117,364,154
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- April Brinkoetter · Hungry Heart Media, Inc.$57,302,265
Research focus
FutureFda ApprovedAgonistFinancial HardshipArthropathiesCartilage DegradationAntidepressive AgentsAttenuatedBindingCellsChondrocytesCartilageClinical ResearchClinical TrialsCollagenCartilage RegenerationCoupledDegenerative PolyarthritisDesensitizationCell GrowthEffective TherapyEnzymesEpiphysial CartilageGallein
Grant awards (5)
Therapeutic targeting of GPCR Gbetagamma-GRK2 in osteoarthritis$337,260
R01 · FY2023 · AR · contact PI
Therapeutic targeting of GPCR Gbetagamma-GRK2 in osteoarthritis$333,887
R01 · FY2022 · AR · contact PI
Therapeutic targeting of GPCR Gbetagamma-GRK2 in osteoarthritis$327,142
R01 · FY2021 · AR · contact PI
Therapeutic targeting of GPCR Gbetagamma-GRK2 in osteoarthritis$337,260
R01 · FY2020 · AR · contact PI
Therapeutic targeting of GPCR Gbetagamma-GRK2 in osteoarthritis$337,260
R01 · FY2019 · AR · contact PI